Page last updated: 2024-11-05

maltol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Maltol is a naturally occurring organic compound with a sweet, caramel-like aroma. It is found in various sources, including malt, coffee, and bark of the Japanese larch tree. Maltol is synthesized commercially by the degradation of sugars or from furfural.
It is used as a flavor enhancer and fragrance in food and beverages, enhancing the taste and aroma of various products like baked goods, candies, and alcoholic drinks.
Maltol has also been found to exhibit antioxidant, anti-inflammatory, and antimicrobial properties. It's ability to protect against oxidative damage has led to its investigation for its potential use in food preservation and as a possible therapeutic agent for neurodegenerative diseases.
Research continues to explore its potential applications in various fields, including pharmaceuticals, cosmetics, and food science.'

maltol: found in bark of young larch trees; isolated from Passiflora incarnata; possesses depressant properties in mice; potentiates hexobarbital-induced narcosis & inhibits spontaneous motor activity; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
PassifloragenusA plant genus of the family Passifloraceae, order Violales, subclass Dilleniidae, class Magnoliopsida. They are vines with ornamental flowers and edible fruit.[MeSH]PassifloraceaeA plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. Many have tendrils in leaf axils. Leaves are alternate. Flowers have 3-5 sepals, petals and stamens. Nearly all species have seeds that bear a fleshy appendage called an aril.[MeSH]

Cross-References

ID SourceID
PubMed CID8369
CHEMBL ID31422
CHEBI ID69438
SCHEMBL ID4815
MeSH IDM0052047

Synonyms (146)

Synonym
HMS3394K09
palatone
3-hydroxy-2-methylpyrone
nsc-2829
corps praline
larixinic acid
vetol
talmon
nsc2829 ,
larixic acid
3-hydroxy-2-methyl-4-pyrone
4h-pyran-4-one, 3-hydroxy-2-methyl-
2-methyl-3-hydroxy-4-pyrone
3-hydroxy-2-methyl-4h-pyran-4-one
wln: t6o dvj b1 cq
3-hydroxy-2-methyl-.gamma.-pyrone
2-methyl-3-hydroxypyrone
2-methyl pyromeconic acid
KBIO1_001483
DIVK1C_006539
NCI60_002320
smr000059093
MLS000069412 ,
SDCCGMLS-0066563.P001
2-methylpyromeconic acid
ai3-18547
SPECTRUM4_001871
maltol (natural)
fema no. 2656
brn 0112169
SPECTRUM_001419
einecs 204-271-8
ccris 3467
3-hydroxy-2-methyl-gamma-pyrone
nsc 2829
2-methyl-3-oxy-gamma-pyrone
BSPBIO_003161
NCGC00178231-01
3-hydroxy-2-methyl-pyran-4-one
3-hydroxy-2-methyl-1,4-pyrone
nsc-404458
nsc404458
NCGC00091223-01
maltol
118-71-8
maltol, natural, >=98.5%, fg
maltol, >=99.0%, fcc, fg
3-hydroxy-2-methyl-4-pyrone, 99%
NCGC00091223-02
KBIO2_001899
KBIO2_007035
KBIOGR_002365
KBIOSS_001899
KBIO2_004467
KBIO3_002381
SPBIO_001749
SPECPLUS_000443
SPECTRUM3_001351
SPECTRUM2_001795
SPECTRUM310025
SPECTRUM5_000462
HMS2052K09
xpctzqvdejyugt-uhfffaoysa-
inchi=1/c6h6o3/c1-4-6(8)5(7)2-3-9-4/h2-3,8h,1h3
e-636
ins-636
veltol
CHEMBL31422
chebi:69438 ,
e636
ins no.636
ksc-11-228-8
KUC106764N
3-hydroxy-2-methylpyran-4-one
BMSE000538
MLS002415738
M0673
STK801686
A804081
AKOS005607790
NCGC00091223-03
NCGC00091223-04
NCGC00091223-05
hsdb 8320
unii-3a9rd92bs4
maltol [nf]
5-18-01-00114 (beilstein handbook reference)
3a9rd92bs4 ,
QSPL 180
tox21_300118
NCGC00259764-01
tox21_202215
dtxsid0025523 ,
cas-118-71-8
dtxcid305523
NCGC00254046-01
BBL011669
MLS001424145
CCG-38443
BP-11468
FT-0615804
PS-4578
AM20080119
maltol [ii]
maltol [fcc]
maltol [mi]
maltol [usp-rs]
maltol [mart.]
maltol [inci]
maltol [fhfi]
S4940
3-hydroxy-2-methyl-4-pyranone
3-hydroxy-2-methyl-gamma -pyrone
2-methyl-3-hydroxy-4-pyranone
3-hydroxy-2-methylpyr-4-one
methyl maltol
3-hydroxyl-2-methyl-4-pyranone
3-hydroxy-2-methyl-4-oxopyrane
NC00350
SCHEMBL4815
2-methyl-3-hydroxy-4h-pyran-4-one
STR01642
2-methyl-3-oxy-.gamma.-pyrone
5-hydroxy-6-methyl-4h-pyran-4-one
W-108539
methylmaltol
OPERA_ID_338
mfcd00006578
sr-01000712383
SR-01000712383-3
maltol, united states pharmacopeia (usp) reference standard
maltol, analytical standard
3-hydroxy-2-methyl-4-pyrone; 3-hydroxy-2-methyl-pyran-4-one; maltol; deferiprone impurity b
maltol (3-hydroxy-2-methyl-4-pyrone)
laricinic acid
3-hydroxy-2-pyran-4-one
fema 2656
3-hydroxy-2-methyl-g-pyrone
SY011358
Q420648
CS-W013504
bdbm50227434
BRD-K40619305-001-12-1
EN300-93557
HY-W012788
Z1255382969

Research Excerpts

Overview

Maltol (MA) is a flavoring agent extracted from red ginseng. The maltol-iron complex is a recently approved drug used for increasing iron intake in the treatment of iron deficiency anemia. Maltol is a common compound formed in the Maillard reaction.

ExcerptReferenceRelevance
"Maltol (MA) is a flavoring agent extracted from red ginseng."( Maltol ameliorates intervertebral disc degeneration through inhibiting PI3K/AKT/NF-κB pathway and regulating NLRP3 inflammasome-mediated pyroptosis.
Chen, W; Feng, X; Gong, Y; He, Z; Hong, Z; Jiang, T; Li, Z; Qiu, J; Wang, M; Wang, Z; Zhang, W; Zheng, X, 2023
)
3.07
"The maltol-iron complex is a recently approved drug used for increasing iron intake in the treatment of iron deficiency anemia, a condition affecting one-third to one-quarter of the world's population."( Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.
Kontoghiorghes, GJ, 2023
)
1.71
"Maltol is a flavor additive that is widely used in the daily diet of humans, and its biosafety attention is concomitantly increasing. "( Binding mechanism of maltol with catalase investigated by spectroscopy, molecular docking, and enzyme activity assay.
Huo, M; Liu, R; Wang, T; Zhao, L; Zong, W, 2020
)
2.32
"Maltol was shown to be a strong enhancer of aluminum accumulation in serum, brain, and bone."( Effect of citric acid and maltol on the accumulation of aluminum in rat brain and bone.
D'Haese, PC; De Broe, ME; de Wolff, FA; van der Voet, GB; van Ginkel, MF, 1993
)
1.31
"Maltol is a common compound formed in the Maillard reaction, but it was very difficult to detect it in previous experiments using actual cookie materials."( Volatile components formed from reaction of sugar and beta-alanine as a model system of cookie processing.
Berhnard, RA; Kawakishi, S; Nishibori, S; Osawa, T, 1998
)
1.02

Effects

Maltol has a caramel-butterscotch odour and is used as a food additive to impart flavour to bread and cakes. Maltol hastens the disappearance of the quinones, possibly by conjugating with them.

Maltol has a caramel-butterscotch odour and is used as a food additive to impart flavour to bread and cakes. Maltol has been shown to increase the neurotoxicity of aluminum, but little is known about its effect on aluminum deposition in the body.

ExcerptReferenceRelevance
"Maltol has a caramel-butterscotch odour and is used as a food additive to impart flavour to bread and cakes."( Mutagenicity of UV-irradiated maltol in Salmonella typhimurium.
Inaba, Y; Ohta, T; Watanabe-Akanuma, M, 2007
)
1.35
"Maltol has an effect on the spectrum of product(s) formed when each catecholamine was oxidized by tyrosinase showing that maltol hastens the disappearance of the quinones, possibly by conjugating with them."( Effect of maltol on the oxidation of DL-DOPA, dopamine, N-acetyldopamine (NADA), and norepinephrine by mushroom tyrosinase.
Ben-Shalom, N; Kahn, V, 1997
)
1.42
"Maltol has potential as a new neuroprotective therapeutic agent for oxidative stress-related ocular diseases, including glaucoma."( Neuroprotective and neurite outgrowth effects of maltol on retinal ganglion cells under oxidative stress.
Hong, S; Iizuka, Y; Kim, CY; Lee, T; Seong, GJ, 2014
)
1.38
"Maltol has a caramel-butterscotch odour and is used as a food additive to impart flavour to bread and cakes."( Mutagenicity of UV-irradiated maltol in Salmonella typhimurium.
Inaba, Y; Ohta, T; Watanabe-Akanuma, M, 2007
)
1.35
"Maltol has been shown to increase the neurotoxicity of aluminum, but little is known about its effect on aluminum deposition in the body."( Effect of citric acid and maltol on the accumulation of aluminum in rat brain and bone.
D'Haese, PC; De Broe, ME; de Wolff, FA; van der Voet, GB; van Ginkel, MF, 1993
)
1.31
"Maltol has an effect on the spectrum of product(s) formed when each catecholamine was oxidized by tyrosinase showing that maltol hastens the disappearance of the quinones, possibly by conjugating with them."( Effect of maltol on the oxidation of DL-DOPA, dopamine, N-acetyldopamine (NADA), and norepinephrine by mushroom tyrosinase.
Ben-Shalom, N; Kahn, V, 1997
)
1.42

Treatment

Oral treatment with maltol or bis(maltolato)oxovanadium(IV) alters the biochemical activity of the rat liver Golgi marker enzyme, i.e., galactosyltransferase (GalT) Maltol pretreatment groups did not show significant cell nuclear condensation and fragmentation.

ExcerptReferenceRelevance
"Maltol pretreatment groups did not show significant cell nuclear condensation and fragmentation, indicating that maltol inhibited CCl₄-induced cell apoptosis."( The Liver Protection Effects of Maltol, a Flavoring Agent, on Carbon Tetrachloride-Induced Acute Liver Injury in Mice via Inhibiting Apoptosis and Inflammatory Response.
He, YF; Hou, JG; Jiang, S; Li, W; Liu, W; Ren, S; Wang, YP; Wang, Z; Zhou, YD, 2018
)
1.49
"Oral treatment with maltol or bis(maltolato)oxovanadium(IV) [BMOV] alters the biochemical activity of the rat liver Golgi marker enzyme, i.e., galactosyltransferase (GalT), and the organelle morphology in a relatively short time. "( Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone.
Dabroś, W; Dziga, D; Gryboś, R; Kordowiak, AM, 2000
)
0.85

Toxicity

Maltol was also toxic in a dose-dependent manner in primary murine fetal hippocampal neurons. Maltol may be used to prevent such toxic effect.

ExcerptReferenceRelevance
" Maltol was also toxic in a dose-dependent manner in primary murine fetal hippocampal neurons at micromolar concentrations."( Maltol (3-hydroxy-2-methyl-4-pyrone) toxicity in neuroblastoma cell lines and primary murine fetal hippocampal neuronal cultures.
Garruto, RM; Hironishi, M; Kordek, R; Yanagihara, R, 1996
)
2.65
" Maltol may be used to prevent such toxic effect."( The protective effects of maltol on cisplatin-induced nephrotoxicity through the AMPK-mediated PI3K/Akt and p53 signaling pathways.
Chen, C; Han, Y; Hou, JG; Hu, JN; Li, W; Mi, XJ; Ren, S; Wang, Z, 2018
)
1.69
"Zinc (Zn) is one of the trace elements, and Zn deficiency causes many adverse effects."( Four-week repeated oral dose toxicity study of zinc maltol in rats.
Akizawa, F; Dogishi, K; Fujiwara, S; Hitomi, M; Kimoto, H; Kondo, S; Moroki, T, 2023
)
1.16

Bioavailability

The results suggest a non-significant enhancement of oral Al bioavailability by citrate and maltolate, some Al complex dissociation in the GI tract, and less absorption of Al than citrate or maltolate. This result suggests that the chemical form of Al strongly influences its bioavailability.

ExcerptReferenceRelevance
" This result suggests that the chemical form of Al strongly influences its bioavailability and that intraperitoneal administration of the Al-maltol complex appears to be useful in creating subacute model of Al accumulation in brain tissue."( Effects of the administration routes and chemical forms of aluminum on aluminum accumulation in rat brain.
Ishii, K; Ogasawara, Y; Sakamoto, T; Takahashi, H; Tanabe, S, 2002
)
0.52
" The results suggest a non-significant enhancement of oral Al bioavailability by citrate and maltolate, some Al complex dissociation in the GI tract, and less absorption of Al than citrate or maltolate."( The influence of citrate, maltolate and fluoride on the gastrointestinal absorption of aluminum at a drinking water-relevant concentration: A 26Al and 14C study.
Harris, WR; Yokel, RA; Zhou, Y, 2008
)
0.87
" These bis-ligand oxovanadium(IV) (VOL(2)) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy."( Vanadium treatment of type 2 diabetes: a view to the future.
LeBel, C; Lichter, J; McNeill, JH; Orvig, C; Scaife, MC; Thompson, KH, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (5 Items)

ItemProcessFrequency
Salted snackscore-ingredient5
Dessertscore-ingredient1
Groceriescore-ingredient1
Condimentscore-ingredient1
Syrupscore-ingredient1

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
4-pyranonesA pyranone based on the structure of 4H-pyran-4-one and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency25.11890.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.66510.177814.390939.8107AID2147
phosphopantetheinyl transferaseBacillus subtilisPotency11.22020.141337.9142100.0000AID1490
AR proteinHomo sapiens (human)Potency19.51050.000221.22318,912.5098AID743035
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency4.46680.707912.194339.8107AID720542
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency45.65470.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency35.55200.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency10.75410.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.56230.000229.305416,493.5996AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency64.61300.023723.228263.5986AID743223
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.77830.035520.977089.1251AID504332
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency7.07953.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency50.88780.000323.4451159.6830AID743066
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency54.76170.000627.21521,122.0200AID743202; AID743219
lamin isoform A-delta10Homo sapiens (human)Potency7.94330.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))IC50 (µMol)199.76301.88004.68805.8600AID1635903
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)199.76300.00002.398310.0000AID1635903
Lactoylglutathione lyaseHomo sapiens (human)Ki223.87200.00122.59479.1400AID74123
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
carbohydrate metabolic processLactoylglutathione lyaseHomo sapiens (human)
regulation of transcription by RNA polymerase IILactoylglutathione lyaseHomo sapiens (human)
glutathione metabolic processLactoylglutathione lyaseHomo sapiens (human)
methylglyoxal metabolic processLactoylglutathione lyaseHomo sapiens (human)
osteoclast differentiationLactoylglutathione lyaseHomo sapiens (human)
negative regulation of apoptotic processLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
lactoylglutathione lyase activityLactoylglutathione lyaseHomo sapiens (human)
protein bindingLactoylglutathione lyaseHomo sapiens (human)
zinc ion bindingLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
extracellular regionPolymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
nucleoplasmLactoylglutathione lyaseHomo sapiens (human)
cytoplasmLactoylglutathione lyaseHomo sapiens (human)
cytosolLactoylglutathione lyaseHomo sapiens (human)
plasma membraneLactoylglutathione lyaseHomo sapiens (human)
extracellular exosomeLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (49)

Assay IDTitleYearJournalArticle
AID74123Inhibition constant of compound against binding of Yeast Glyoxalase I1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1635904Inhibition of 8-histidine tagged influenza virus H1N1 N-terminal PA endonuclease expressed in Escherichia coli BL21 cells at 200 uM using single-stranded 5'-FAM fluorophore/3'-TAMRA quencher)-labeled 17-mer ssDNA-oligomer substrate measured over 45 mins b2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fragment-Based Identification of Influenza Endonuclease Inhibitors.
AID1635905Inhibition of 8-histidine tagged influenza virus H1N1 N-terminal PA endonuclease expressed in Echerichia coli BL21 cells at 50 uM using single-stranded 5'-FAM fluorophore/3'-TAMRA quencher)-labeled 17-mer ssDNA-oligomer substrate measured over 45 mins by 2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fragment-Based Identification of Influenza Endonuclease Inhibitors.
AID24630Compound was tested for their chelating potential with gallium-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1635903Inhibition of 8-histidine tagged influenza virus H1N1 N-terminal PA endonuclease expressed in Escherichia coli BL21 cells using single-stranded 5'-FAM fluorophore/3'-TAMRA quencher)-labeled 17-mer ssDNA-oligomer substrate measured over 45 mins by FRET ana2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fragment-Based Identification of Influenza Endonuclease Inhibitors.
AID616299Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID616386Antioxidant activity assessed DPPH scavenging activity at 500 uM2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID24629Compound was tested for their chelating potential with Iron-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID24628Compound was tested for their chelating potential with Indium-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID24627Compound was tested for their chelating potential (free ligand) determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID80624Percent relaxation using isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID616383Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID80631Percent relaxation of isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (171)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (11.11)18.7374
1990's23 (13.45)18.2507
2000's47 (27.49)29.6817
2010's52 (30.41)24.3611
2020's30 (17.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.59 (24.57)
Research Supply Index5.17 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index106.76 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (63.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other170 (97.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]